COVID-19 vaccination before or during pregnancy results in high, sustained maternal neutralizing activity to SARS-CoV-2 wild-type and Delta/Omicron variants of concern, particularly following a booster dose or infection

被引:1
|
作者
Mahyuddin, Aniza P. [1 ]
Swa, Hannah L. F. [2 ]
Weng, Ruifen [2 ]
Zhang, Jingxian [2 ]
Dhanaraj, Janice P. [2 ]
Sesurajan, Binny P. [1 ,6 ]
Rauff, Mary [1 ,3 ]
Dashraath, Pradip [1 ,3 ]
Kanneganti, Abhiram [3 ]
Lee, Rachel [3 ]
Wang, Lin-Fa [4 ,5 ]
Young, Barnaby E. [5 ,6 ,7 ,8 ,9 ]
Tambyah, Paul A. [1 ,9 ,10 ]
Lye, David C. [5 ,6 ,7 ,8 ,9 ]
Chai, Louis Y. A. [9 ,10 ]
Yee, Sidney [11 ]
Choolani, Mahesh [1 ,3 ]
Mattar, Citra N. Z. [1 ,3 ]
机构
[1] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Obstet & Gynaecol, 1E Kent Ridge Rd,NUHS Tower Block,Level 12, Singapore 119228, Singapore
[2] Agcy Sci Technol & Res, Diagnost Dev Hub, Singapore, Singapore
[3] Natl Univ Hlth Syst, Natl Univ Hosp, Dept Obstet & Gynaecol, Singapore, Singapore
[4] Duke NUS Med Sch, Programme Emerging Infect Dis, Singapore, Singapore
[5] Natl Ctr Infect Dis, Programme Res Epidem Preparedness & Response PREPA, Singapore, Singapore
[6] Natl Ctr Infect Dis, Singapore, Singapore
[7] Tan Tock Seng Hosp, Dept Infect Dis, Singapore, Singapore
[8] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore
[9] Natl Univ Singapore, Yong Loo Lin Sch Med, Infect Dis Translat Res Program, Singapore, Singapore
[10] Natl Univ Singapore Hosp, Natl Univ Hlth Syst, Dept Med, Div Infect Dis, Singapore, Singapore
[11] Agcy Sci Technol & Res, Innovatione & Enterprise, Connexis North Tower, Singapore, Singapore
基金
英国医学研究理事会; 新加坡国家研究基金会;
关键词
SARS-CoV-2; Pregnancy; Vaccine effectiveness; Delta; Omicron; Surrogate virus neutralization; OMICRON;
D O I
10.1016/j.ijid.2024.107121
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To investigate multi-dose and timings of COVID-19 vaccines in preventing antenatal infection. Design: Prospective observational study investigating primary vaccinations, boosters, antenatal COVID-19 infections, neutralizing antibody (Nab) durability, and cross-reactivity to Delta and Omicron variants of concern (VOCs). Results: Ninety-eight patients completed primary vaccination prepregnancy (29.6%) and antenatally (63.3%), 24.2% of whom had antenatal COVID-19, while 7.1% were unvaccinated (28.6% had antenatal COVID-19). None had severe COVID-19. Prepregnancy vaccination resulted in vaccination-to-infection delay of 23.3 weeks, which extended to 45.2 weeks with a booster, compared to 16.9 weeks following antenatal vaccination ( P < 0.001). Infections occurred at 26.2 weeks gestation in women vaccinated prepregnancy compared to 36.2 weeks gestation in those vaccinated during pregnancy ( P < 0.007). The risk of COVID-19 infection was higher without antenatal vaccination (hazard ratio [HR] 14.6, P = 0.05) and after prepregnancy vaccination without a booster (HR 10.4, P = 0.002). Antenatal vaccinations initially led to high Nab levels, with mild waning but subsequent rebound. Significant Nab enhancement occurred with a third-trimester booster. Maternal-neonatal Nab transfer was efficient (transfer ratio > 1), and crossreactivity to VOCs was observed. Conclusion: Completing vaccination during any trimester delays COVID-19 infection and maintains effective neutralizing activity throughout pregnancy, with robust cross-reactivity to VOCs and efficient maternal-neonatal transfer. (c) 2024 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页数:9
相关论文
共 50 条
  • [1] A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant
    Wolz, Olaf-Oliver
    Kays, Sarah-Katharina
    Junker, Helga
    Koch, Sven D.
    Mann, Philipp
    Quintini, Gianluca
    Von Eisenhart-Rothe, Philipp
    Oostvogels, Lidia
    VACCINES, 2022, 10 (04)
  • [2] Neutralizing Activity Against SARS-CoV-2 Delta and Omicron Variants Following a Third BNT162b2 Booster Dose According to Three Homologous or Heterologous COVID-19 Vaccination Schedules
    Choi, Ju-yeon
    Lee, Young Jae
    Ko, Jae-Hoon
    Kim, Su-Hwan
    Kim, Hye-Jin
    Lee, Hye Won
    Jeong, Hyeonji
    Kim, Tae-Yong
    Jang, Yeong Gyeong
    Hong, Hyo-jeong
    Kim, Min-Seong
    Lee, Sang Eun
    Kim, Yong Guan
    Chung, Eun Joo
    Lim, Heeji
    Jang, Sundong
    Kim, Kwangwook
    Kim, Sung Soon
    Ahn, Jin Young
    Choi, Jun Yong
    Kim, Yong Chan
    Park, Yoon Soo
    Peck, Kyong Ran
    Kim, Byoungguk
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 12
  • [3] Neutralizing antibodies and safety of a COVID-19 vaccine against SARS-CoV-2 wild-type and Omicron variants in solid cancer patients
    Chewaskulyong, Busyamas
    Satjaritanun, Pattarapong
    Ketpueak, Thanika
    Suksombooncharoen, Thatthan
    Charoentum, Chaiyut
    Nuchpong, Nuttaphoom
    Tantraworasin, Apichat
    PLOS ONE, 2024, 19 (11):
  • [4] The third booster vaccination dose against COVID-19: indication for circulating SARS-CoV-2 variants
    Rahimi, Farid
    Bezmin Abadi, Amin Talebi
    FUTURE VIROLOGY, 2021, 16 (12) : 781 - 784
  • [5] Effect of Previous COVID-19 Vaccination on Humoral Immunity 3 Months after SARS-CoV-2 Omicron Infection and Booster Effect of a Fourth COVID-19 Vaccination 2 Months after SARS-CoV-2 Omicron Infection
    Kim, Jinsoo
    Seo, Hyeonji
    Kim, Han-Wool
    Kim, Dongbum
    Kwon, Hyung-Joo
    Kim, Yong-Kyun
    VIRUSES-BASEL, 2022, 14 (11):
  • [6] Infection with Wild Type SARS-CoV-2 Combined with Vaccination Augments Neutralizing Antibody Levels Against Variants Including Omicron
    O'Shea, Daniel
    Schuler, Charles
    Chen, Jesse
    Troost, Jonathan
    Wong, Pamela
    Chen, Kelsea
    Peng, Westley
    Gherasim, Carmen
    Manthei, David
    Valdez, Riccardo
    Baldwin, James
    O'Shea, Kelly
    Baker, James
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB24 - AB24
  • [7] A Comparative Study of Clinical Characteristics and COVID-19 Vaccine Effectiveness Against SARS-CoV-2 Variants: Wild-Type, Alpha, Delta, and Omicron in Beijing, China
    Li, Junnan
    Peng, Wenjuan
    Zhang, Yuting
    Liu, Shunai
    Han, Ming
    Song, Rui
    Zhang, Yuanyuan
    Jin, Ronghua
    Wang, Xi
    INFECTION AND DRUG RESISTANCE, 2024, 17 : 5147 - 5161
  • [8] Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
    Perez-Then, Eddy
    Lucas, Carolina
    Monteiro, Valter Silva
    Miric, Marija
    Brache, Vivian
    Cochon, Leila
    Vogels, Chantal B. F.
    Malik, Amyn A.
    De la Cruz, Elena
    Jorge, Aidelis
    De los Santos, Margarita
    Leon, Patricia
    Breban, Mallery, I
    Billig, Kendall
    Yildirim, Inci
    Pearson, Claire
    Downing, Randy
    Gagnon, Emily
    Muyombwe, Anthony
    Razeq, Jafar
    Campbell, Melissa
    Ko, Albert, I
    Omer, Saad B.
    Grubaugh, Nathan D.
    Vermund, Sten H.
    Iwasaki, Akiko
    NATURE MEDICINE, 2022, 28 (03) : 481 - +
  • [9] Effect of Hypertension Comorbidity on Clinical Characteristics of COVID-19 Patients Infected by the Wild-Type, the Delta or Omicron Variant SARS-CoV-2
    Zhang, Jinhui
    Zhang, Jianguo
    Tao, Zhimin
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2022, 23 (12)
  • [10] Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
    Eddy Pérez-Then
    Carolina Lucas
    Valter Silva Monteiro
    Marija Miric
    Vivian Brache
    Leila Cochon
    Chantal B. F. Vogels
    Amyn A. Malik
    Elena De la Cruz
    Aidelis Jorge
    Margarita De los Santos
    Patricia Leon
    Mallery I. Breban
    Kendall Billig
    Inci Yildirim
    Claire Pearson
    Randy Downing
    Emily Gagnon
    Anthony Muyombwe
    Jafar Razeq
    Melissa Campbell
    Albert I. Ko
    Saad B. Omer
    Nathan D. Grubaugh
    Sten H. Vermund
    Akiko Iwasaki
    Nature Medicine, 2022, 28 : 481 - 485